December 2024 in “Nutrients” Skin, hair, and nail changes can help detect eating disorders early.
November 2024 in “Frontiers in Medicine” Cirrhosis affects quality of life with various symptoms, requiring a holistic, multidisciplinary approach for management.
November 2024 in “Clinical Cosmetic and Investigational Dermatology” Rosemary oil may effectively treat hair loss with fewer side effects, but more research is needed.
October 2024 in “Journal of the Endocrine Society” ACTH-dependent Cushing's syndrome linked to metastatic cervical cancer is rare and has high risks.
October 2024 in “Journal of the Endocrine Society” Metastatic cervical cancer can cause rare, severe Cushing's syndrome with high risk of death.
August 2024 in “Frontiers in Public Health” Alopecia Areata severely impacts mental health, causing anxiety and depression, affecting quality of life.
June 2024 in “Trends in Urology & Men s Health” Post-finasteride syndrome is rare but serious and should be taken seriously.
January 2024 in “JEADV clinical practice” Gender-affirming dermatology treatments generally improve mental well-being for transgender individuals, but more research is needed.
December 2023 in “European Journal of Psychology Open” Men who are perfectionists feel more upset about baldness, partly due to aging anxiety.
November 2023 in “Frontiers in Neuroendocrinology” Some people experience lasting sexual, psychological, and sleep problems after using finasteride or SSRI antidepressants, possibly due to similar underlying causes.
November 2023 in “Australasian journal of dermatology” Dermatologists are essential in helping transgender and gender diverse patients with skin and hair issues related to gender affirmation and hormone therapy.
October 2023 in “Georgetown medical review” Finasteride and Dutasteride can improve hair growth in male baldness but may cause temporary sexual dysfunction and possibly affect fertility.
New treatments for hair loss should target eight main causes and use specific plant compounds and peptides for better results.
July 2023 in “The Journal of Clinical Endocrinology and Metabolism” Gender-affirming hormone therapy improves physical performance in trans men to the level of cisgender men, while in trans women, it increases fat mass and decreases muscle mass, with no advantage in physical performance after 2 years.
July 2023 in “Dermatology and Therapy” 5-Alpha Reductase Inhibitors are effective for male hair loss and some skin conditions, but their effectiveness in women and safety concerns require careful use.
June 2023 in “Clinical and Experimental Dermatology” Gender-affirming hormone therapy changes hair growth in transgender people, with feminizing therapy reducing hair and masculinizing therapy increasing it, but sometimes additional treatment is needed.
January 2022 in “Turkiye Klinikleri Journal of Dermatology” The Turkish version of the MAIA-2 Scale is valid and reliable for patients at a dermatology clinic.
January 2018 in “Surgical and Cosmetic Dermatology” Finasteride and dutasteride are effective for male hair loss and enlarged prostate but may cause reversible sexual side effects.
January 2015 in “Вестник дерматологии и венерологии” Patients with non-scarring hair loss often have emotional disorders.
April 2023 in “JOJ dermatology & cosmetics” The conclusion is that a team of skin doctors and psychiatrists is needed to better treat patients with mind-skin disorders.
December 2022 in “JAMA network open” 5α-Reductase inhibitors may increase depression risk but not dementia or suicide.
January 2022 in “Springer eBooks” January 2021 in “Menoufia Medical Journal (Print)” Androgenetic alopecia negatively affects emotions and self-confidence, especially in younger people.
26 citations,
September 2009 in “Psychosomatics” A girl initially thought to have a psychiatric disorder was later found to have a lupus-related condition, which improved with proper treatment.
August 2012 in “Pharmaceutical Medicine” The document concludes that various medications and treatments can have significant, sometimes adverse, effects on health outcomes.
4 citations,
November 2001 in “Journal of Neuropsychiatry” Divalproex sodium can sometimes worsen behavior in some patients.
November 2001 in “The Journal of neuropsychiatry and clinical neurosciences/The journal of neuropsychiatry and clinical neurosciences” Divalproex sodium can unexpectedly cause agitation and hyperactivity in some patients.
November 2003 in “Journal of Dermatology” Finasteride's link to depression is questionable due to study flaws and potential bias.
3 citations,
April 2021 in “Journal of Medicinal Chemistry” Finasteride may affect PNMT, causing side effects.
November 2019 in “Harper's Textbook of Pediatric Dermatology” The document is a detailed medical reference on skin and genetic disorders.